Can Harvard Bioscience, Inc. (HBIO)’s Tomorrow be Different? The Stock Just Broke Its High

January 23, 2018 - By Maria Brooks

Investors sentiment decreased to 0.91 in Q3 2017. Its down 0.18, from 1.09 in 2017Q2. It worsened, as 8 investors sold Harvard Bioscience, Inc. shares while 15 reduced holdings. 7 funds opened positions while 14 raised stakes. 21.49 million shares or 1.39% more from 21.19 million shares in 2017Q2 were reported.
537,467 are held by Granahan Invest Ma. Gsa Ltd Liability Partnership has invested 0.05% in Harvard Bioscience, Inc. (NASDAQ:HBIO). Spark Inv Mngmt Limited Liability reported 69,600 shares. Nationwide Fund owns 8,872 shares for 0% of their portfolio. Goldman Sachs Grp Inc has 21,884 shares. Moreover, Schwab Charles Inv Mngmt has 0% invested in Harvard Bioscience, Inc. (NASDAQ:HBIO). Heartland Advsr Incorporated reported 2.00M shares stake. Deutsche Bancshares Ag has invested 0% in Harvard Bioscience, Inc. (NASDAQ:HBIO). Dimensional Fund Limited Partnership holds 1.74 million shares or 0% of its portfolio. United Services Automobile Association holds 105,178 shares. Meristem Limited Liability Partnership holds 0.02% or 12,368 shares. Sei Investments Company holds 735 shares or 0% of its portfolio. Blackrock accumulated 0% or 1.54 million shares. Ancora Advsrs Ltd Co owns 0.04% invested in Harvard Bioscience, Inc. (NASDAQ:HBIO) for 191,278 shares. Price T Rowe Associates Md holds 0% in Harvard Bioscience, Inc. (NASDAQ:HBIO) or 28,200 shares.

The stock of Harvard Bioscience, Inc. (NASDAQ:HBIO) hit a new 52-week high and has $4.43 target or 3.00 % above today’s $4.30 share price. The 6 months bullish chart indicates low risk for the $149.99 million company. The 1-year high was reported on Jan, 23 by Barchart.com. If the $4.43 price target is reached, the company will be worth $4.50M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock increased 10.26% or $0.4 during the last trading session, reaching $4.3. About 440,112 shares traded or 632.93% up from the average. Harvard Bioscience, Inc. (NASDAQ:HBIO) has declined 25.93% since January 23, 2017 and is downtrending. It has underperformed by 42.63% the S&P500.

Analysts await Harvard Bioscience, Inc. (NASDAQ:HBIO) to report earnings on March, 8. They expect $0.03 EPS, up 200.00 % or $0.02 from last year’s $0.01 per share. HBIO’s profit will be $1.05M for 35.83 P/E if the $0.03 EPS becomes a reality. After $0.01 actual EPS reported by Harvard Bioscience, Inc. for the previous quarter, Wall Street now forecasts 200.00 % EPS growth.

Harvard Bioscience, Inc. (NASDAQ:HBIO) Ratings Coverage

Among 2 analysts covering Harvard Bioscience Inc (NASDAQ:HBIO), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Harvard Bioscience Inc had 2 analyst reports since July 28, 2015 according to SRatingsIntel. As per Tuesday, July 28, the company rating was initiated by Benchmark. The stock of Harvard Bioscience, Inc. (NASDAQ:HBIO) has “Buy” rating given on Thursday, November 17 by Singular Research.

More recent Harvard Bioscience, Inc. (NASDAQ:HBIO) news were published by: Globenewswire.com which released: “Harvard Bioscience Reports Third Quarter 2017 Financial Results” on October 26, 2017. Also Seekingalpha.com published the news titled: “Harvard Bioscience’s (HBIO) CEO Jeffrey Duchemin on Q2 2017 Results – Earnings …” on July 27, 2017. Globenewswire.com‘s news article titled: “Harvard Bioscience To Acquire Data Sciences International and Sells Denville …” with publication date: January 22, 2018 was also an interesting one.

Harvard Bioscience, Inc. develops, manufactures, and markets scientific instruments, systems, and lab consumables used in life science basic research, drug discovery, and clinical and environmental testing. The company has market cap of $149.99 million. The firm offers cell and animal physiology products, such as syringe pump and peristaltic pump products, as well as a range of instruments and accessories, including surgical products, infusion systems, microdialysis instruments, behavior research systems, and isolated organ and tissue bath systems, as well as in vivo and in vitro electrophysiology recording, stimulation, and analysis systems for tissue, organ, and animal based lab research under the Harvard Apparatus, CMA Microdialysis, Panlab, Coulbourn, Hugo-Sachs, InBreath Bioreactor, MCS, TBSI, and HEKA brands. It currently has negative earnings. It also provides products for molecular biology labs comprising pipettes and pipette tips, gloves, gel electrophoresis equipment and reagents, autoradiography films, thermal cycler accessories and reagents, sample preparation columns, tissue culture products, and general lab equipment and consumables under the Denville Scientific and other brands.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: